Orchestra BioMed Holdings, Inc.

NASDAQ:OBIO

Biotechnology

Healthcare
$7.46 +1.16%

+$0.05 today

Market cap
$587.14M
Beta
0.50
P/E (TTM)
-2.8
EPS (TTM)
-$1.42
52W Low $2.20High $5.42

Volume 1.20M

Average 0.22M

OBIO Net Income

Bottom-line profit after all expenses, interest, and taxes.

Orchestra BioMed Holdings, Inc.NASDAQ: OBIO

Net Income · Q1 FY2026 · quarter ended Mar 2026

Net income remains negative

Q1 FY2026 net income was -$20.69M, compared with -$18.76M a year earlier. Trailing-twelve-month net income was -$54.64M.

Context

  • Net income amounted to 157.4% of revenue in FY2025, down 2155.9 pp from a year earlier.
  • Net income grew in size in 2 of the last 3 fiscal years.

What to watch

Whether net income reaches the consensus estimate from 6 analysts of -$65.29M (-23.9%) for the fiscal year ending Dec 2026, a slowdown from the +13.6% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$20.69M-431.3% QoQ
Last fiscal yearDec 2025
-$52.7M+13.6% YoY
LTMMar 2026
-$54.64M+17.6% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-10.3%-130725.5%-130715.1 pp
1 year+13.6%-23.9%-37.5 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the income statement

Latest · FY2025
(52.7M) USD
Year-over-year change
+13.6%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How OBIO compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +17.6% is the 5th highest of 11, against a peer median of +12.0%.
  • Net income amounts to 167.0% of revenue for OBIO, versus a peer median of 889.5%.
OBIO Competitors
Net Income for OBIO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
EPRXEupraxia Pharmaceuticals Inc.LTM Mar 2026-$42.49M USD-62.1%——
OBIOOrchestra BioMed Holdings, Inc.LTM Mar 2026-$54.64M USD+17.6%—167.0%
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 2026-$61.98M USD+35.7%—89.6%
TARAProtara Therapeutics, Inc.LTM Mar 2026-$63.31M USD-39.4%——
IVVDInvivyd, Inc.LTM Mar 2026-$77.6M USD+45.6%—138.9%
PRLDPrelude Therapeutics IncorporatedLTM Mar 2026-$77.8M USD+39.1%—465.3%
PYXSPyxis Oncology, Inc.LTM Mar 2026-$81.74M USD+14.2%—589.8%
TNYATenaya Therapeutics, Inc.LTM Mar 2026-$83.01M USD+21.5%—36891.1%
AVTXAvalo Therapeutics, Inc.LTM Mar 2026-$84.74M USD-216.1%—143627.1%
CRBUCaribou Biosciences, Inc.LTM Mar 2026-$133.22M USD+9.9%—1189.1%
IVAInventiva S.A.FY2025-€340.16M EUR-84.7%—7587.8%
Peer median (excluding OBIO) —+12.0%—889.5%

Competitors are the stored peer set for OBIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue(782K)3.53M2.76M2.64M33.48M
Cost of Revenue199K322K186K204K190K
Gross Profit(981K)3.21M2.57M2.43M33.29M
Gross Margin125.4%90.9%93.3%92.3%99.4%
Research & Development12.89M21.95M33.82M42.8M58.19M
Selling, General & Admin7.93M13.92M20.26M23.93M26.91M
Operating Expenses20.82M35.87M54.08M66.74M85.1M
Depreciation & Amortization181K222K287K308K327K
EBITDA(21.91M)(33.39M)(48.83M)(60.72M)(51.23M)
EBITDA Margin2801.3%-945.0%-1769.3%-2301.6%-153.0%
Operating Income(21.8M)(32.66M)(51.51M)(64.3M)(51.81M)
Operating Margin2787.6%-924.3%-1866.2%-2437.5%-154.7%
Interest Income050K3.85M3.36M0
Interest Expense927K0001.15M
Other Income / Expenses(1.22M)(951K)2.39M3.28M(894K)
Income Before Tax(23.01M)(33.61M)(49.12M)(61.02M)(52.7M)
Pre-Tax Margin2943.0%-951.3%-1779.7%-2313.3%-157.4%
Income Tax Expense00000
Net Income(23.01M)(33.61M)(49.12M)(61.02M)(52.7M)
Net Margin2943.0%-951.3%-1779.7%-2313.3%-157.4%
EPS (Basic)(0.02)(1.32)(1.48)(1.66)(1.38)
EPS (Diluted)(0.02)(1.32)(1.48)(1.66)(1.38)
Weighted Avg Shares20.45M25.47M33.23M36.82M38.39M
Weighted Avg Shares (Diluted)20.45M25.47M33.23M36.82M38.39M

Orchestra BioMed Holdings, Inc.

NASDAQ:OBIO

Intrinsic Alpha fair value

Locked

Current Price

$7.46

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.